Amphastar Pharma (AMPH) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at BMO Capital
March 13, 2019 6:36 AM EDTBMO Capital analyst Gary Nachman raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $21.00) while maintaining a Market Perform rating.
4Q18 results were good overall, although the quarter did benefit from a couple of one-timers (Enoxaparin and insulin API).Management... More